IL97054A - תכשירי רוקחות המכילים בוספירון לטיפול בהפרעות נשימה תרדמתיות - Google Patents
תכשירי רוקחות המכילים בוספירון לטיפול בהפרעות נשימה תרדמתיותInfo
- Publication number
- IL97054A IL97054A IL9705491A IL9705491A IL97054A IL 97054 A IL97054 A IL 97054A IL 9705491 A IL9705491 A IL 9705491A IL 9705491 A IL9705491 A IL 9705491A IL 97054 A IL97054 A IL 97054A
- Authority
- IL
- Israel
- Prior art keywords
- buspirone
- sleep
- treatment
- sleep apneas
- apneas
- Prior art date
Links
- 201000002859 sleep apnea Diseases 0.000 title claims abstract description 25
- 238000011282 treatment Methods 0.000 title claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229960002495 buspirone Drugs 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 229960001768 buspirone hydrochloride Drugs 0.000 claims description 5
- 208000008784 apnea Diseases 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000001797 obstructive sleep apnea Diseases 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000034972 Sudden Infant Death Diseases 0.000 description 2
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000003169 respiratory stimulant agent Substances 0.000 description 2
- 229940066293 respiratory stimulants Drugs 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- -1 8- [4- [4-( 1-pyrimidinyl )-l-piperazinyl]butyl] -8-azaspiro[4,5]decane-7,9-dione hydrochloride Chemical compound 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010067775 Upper airway obstruction Diseases 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940060734 buspirone hydrochloride 5 mg Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47980390A | 1990-02-12 | 1990-02-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL97054A0 IL97054A0 (en) | 1992-03-29 |
| IL97054A true IL97054A (he) | 1995-10-31 |
Family
ID=23905511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9705491A IL97054A (he) | 1990-02-12 | 1991-01-25 | תכשירי רוקחות המכילים בוספירון לטיפול בהפרעות נשימה תרדמתיות |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0442423B1 (he) |
| JP (1) | JP3168543B2 (he) |
| KR (1) | KR910015300A (he) |
| AT (1) | ATE116854T1 (he) |
| CA (1) | CA2036055A1 (he) |
| DE (1) | DE69106543T2 (he) |
| DK (1) | DK0442423T3 (he) |
| ES (1) | ES2069758T3 (he) |
| GR (1) | GR3015716T3 (he) |
| HK (1) | HK1005016A1 (he) |
| HU (1) | HUT56496A (he) |
| IL (1) | IL97054A (he) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631017A (en) * | 1993-03-26 | 1997-05-20 | Beth Israel Deaconess Medical Center, Inc. | Topical application of buspirone for treatment of pathological conditions associated with immune responses |
| US5484788A (en) * | 1993-03-26 | 1996-01-16 | Beth Israel Hospital Association | Buspirone as a systemic immunosuppressant |
| US5637314A (en) * | 1995-06-07 | 1997-06-10 | Beth Israel Deaconess Medical Center, Inc. | Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis |
| DK1066036T3 (da) * | 1998-02-27 | 2006-08-21 | Univ Illinois | Midler med serotoninrelateret aktivitet til behandling af sövnapnö |
| US7160898B2 (en) | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
| US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
| US8512751B2 (en) | 2004-12-20 | 2013-08-20 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
| WO2007006003A2 (en) | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| AU2007233041B2 (en) | 2006-03-31 | 2013-05-02 | Sepracor Inc. | Preparation of chiral amides and amines |
| CN102573823B (zh) * | 2009-05-13 | 2015-01-07 | 桑诺维恩药品公司 | 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途 |
-
1991
- 1991-01-25 IL IL9705491A patent/IL97054A/he not_active IP Right Cessation
- 1991-02-06 JP JP10059991A patent/JP3168543B2/ja not_active Expired - Fee Related
- 1991-02-08 CA CA002036055A patent/CA2036055A1/en not_active Abandoned
- 1991-02-11 DK DK91101888.5T patent/DK0442423T3/da active
- 1991-02-11 DE DE69106543T patent/DE69106543T2/de not_active Expired - Fee Related
- 1991-02-11 KR KR1019910002288A patent/KR910015300A/ko not_active Withdrawn
- 1991-02-11 ES ES91101888T patent/ES2069758T3/es not_active Expired - Lifetime
- 1991-02-11 HU HU91436A patent/HUT56496A/hu unknown
- 1991-02-11 AT AT91101888T patent/ATE116854T1/de not_active IP Right Cessation
- 1991-02-11 EP EP91101888A patent/EP0442423B1/en not_active Expired - Lifetime
-
1995
- 1995-04-07 GR GR950400847T patent/GR3015716T3/el unknown
-
1998
- 1998-05-15 HK HK98104204A patent/HK1005016A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2036055A1 (en) | 1991-08-13 |
| ES2069758T3 (es) | 1995-05-16 |
| EP0442423A1 (en) | 1991-08-21 |
| DE69106543T2 (de) | 1995-05-11 |
| JP3168543B2 (ja) | 2001-05-21 |
| IL97054A0 (en) | 1992-03-29 |
| DK0442423T3 (da) | 1995-03-20 |
| HU910436D0 (en) | 1991-08-28 |
| EP0442423B1 (en) | 1995-01-11 |
| ATE116854T1 (de) | 1995-01-15 |
| KR910015300A (ko) | 1991-09-30 |
| GR3015716T3 (en) | 1995-07-31 |
| HUT56496A (en) | 1991-09-30 |
| JPH0826997A (ja) | 1996-01-30 |
| DE69106543D1 (de) | 1995-02-23 |
| HK1005016A1 (en) | 1998-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6432956B1 (en) | Method for treatment of sleep apneas | |
| US20220151975A1 (en) | Low-Dose Doxepin For Treatment Of Sleep Disorders In Elderly Patients | |
| EP1001760B1 (en) | Composition for controlling mood disorders in healthy individuals | |
| US4640921A (en) | Treatment of sexual dysfunction with buspirone | |
| TW200400821A (en) | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient | |
| IL97054A (he) | תכשירי רוקחות המכילים בוספירון לטיפול בהפרעות נשימה תרדמתיות | |
| TW201929859A (zh) | 夜間頻尿治療劑 | |
| HK1005016B (en) | Use of buspirone in sleep apneas | |
| IL97053A (he) | תכשירי רוקחות המכילים אזאפירונים לטיפול בהפרעות נשימה תרדמתיות | |
| Campbell | Inhibition of anaphylactic shock by acetylsalicylic acid | |
| Pascoe et al. | Arterial hypertension associated with topical ocular use of phenylephrine in dogs | |
| EA006776B1 (ru) | Фармацевтическая композиция для лечения диабетической невропатии | |
| WO2000006163A1 (en) | Improved method for treatment of sleep-related respiratory disorders | |
| IL93371A (he) | תמיסות פנטאמידין המיוצבות על ידי בופר אצטאט | |
| Gray et al. | Protoveratrine A in treatment of hypertension | |
| US2995489A (en) | Method of obtaining preanesthetic sedation and drying with 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid | |
| JPH04282313A (ja) | 血圧降下剤 | |
| Gale | The clinical use of methylphenidate for central stimulation in oversedated patients | |
| Krasno et al. | The Inhalation of Norisodrine Sulfate Dust | |
| US20110076334A1 (en) | Methods and compositions for treatment of raynaud's phenomenon | |
| Committee on Drugs | Precautions concerning the use of theophylline | |
| Booker | Blastomycosis-induced respiratory failure: The successful application of continuous positive airway pressure | |
| JPH0219318A (ja) | 疝痛及び生歯に対する治療 | |
| Vanhaesebrouck et al. | Case report: Neonatal transient respiratory depression after maternal urapidil infusion for hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |